目的分析培美曲塞单药治疗老年晚期肺腺癌患者的近期疗效和不良反应。方法 40例经过多周期化疗或分子靶向治疗后肿瘤进展的老年晚期肺腺癌患者,培美曲塞500 mg/m2静脉滴注,第1天,每21天为1个周期,并口服地塞米松、叶酸和肌内注射维生素B12以减轻不良反应。完成2个周期以上化疗后评价疗效和不良反应。根据实体瘤疗效评价标准(RECIST)对客观缓解率进行评价。结果 40例患者中,部分缓解13例(32.5%),疾病稳定15例(37.5%),疾病进展12例(30.0%),最常见的不良反应为I~II度骨髓抑制。非血液学毒性反应较轻,患者耐受性良好。结论对于老年晚期复发肺腺癌患者,给予培美曲塞解救治疗有临床获益。 Objective To analyze the short-term curative effect and adverse reactions of pemetrexed monotherapy in elderly patients with advanced lung adenocarcinoma. Methods Forty elderly patients with advanced lung adenocarcinoma who underwent multi-cycle chemotherapy or molecular targeted therapy were treated with pemetrexed 500 mg / m 2 intravenously on the first day and every 21 days for one cycle. Dexamethasone, folic acid and intramuscular injection of vitamin B12 to reduce adverse reactions. Complete chemotherapy after 2 cycles to evaluate efficacy and adverse reactions. Objective response rates were evaluated according to RECIST. Results Of the 40 patients, 13 (32.5%) were partially relieved, 15 (37.5%) were stable, 12 (30.0%) were disease progression, and the most common adverse reactions were myelosuppression with grade II to II. Non-hematologic toxicities are mild and patients are well tolerated. Conclusion For the elderly patients with recurrent advanced lung adenocarcinoma, pemetrexed rescue treatment of clinical benefit.